Clinical trial
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
NCT00211185 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00211185 |
|---|---|
| Title | A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma |
| Official title | A Pilot Phase II Study to Determine the Safety and Efficacy of the Combination of ONTAK With CHOP in Peripheral T-Cell Lymphoma. |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, T-Cell, Peripheral |
| Intervention type | Drug, Other |
| Interventions | Denileukin diftitox, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Pegfilgrastim |
| Enrollment | 49 |
| Start date | Mar 14, 2004 |
| Primary completion | Aug 1, 2008 |
| Completion | Dec 23, 2009 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 18, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: